MX9701229A - Antifungicos de tetrahidrofurano. - Google Patents

Antifungicos de tetrahidrofurano.

Info

Publication number
MX9701229A
MX9701229A MX9701229A MX9701229A MX9701229A MX 9701229 A MX9701229 A MX 9701229A MX 9701229 A MX9701229 A MX 9701229A MX 9701229 A MX9701229 A MX 9701229A MX 9701229 A MX9701229 A MX 9701229A
Authority
MX
Mexico
Prior art keywords
independently
tetrahydrofuran antifungals
convertible
vivo
treating
Prior art date
Application number
MX9701229A
Other languages
English (en)
Inventor
Anil K Saksena
Viyyoor M Girijavallabhan
Raymond G Lovey
Russell E Pike
Haiyan Wang
Yi-Tsung Liu
Ashit K Ganguly
Frank Bennett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/459,225 external-priority patent/US5710154A/en
Priority claimed from US08/459,145 external-priority patent/US5693626A/en
Priority claimed from US08/458,543 external-priority patent/US5714490A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9701229A publication Critical patent/MX9701229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un compuesto representado por la formula I (Ver Formula) donde X es independientemente ambas F o ambos C1 o X es independientemente F y el otro es independientemente Cl R1 es un grupo (C4-C5) alquilo de cadena ramificada o de cadena no ramificada sustituida por uno o dos grupos de éster aminoácido convertible in vivo en un grupo hidroxilo o su sal farmacéuticamente aceptable y sus composiciones utiles para tratar y/o prevenir las infecciones fungicidas.
MX9701229A 1995-06-02 1996-05-30 Antifungicos de tetrahidrofurano. MX9701229A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/459,225 US5710154A (en) 1993-12-21 1995-06-02 Tetrahydrofuran antifungals
US08/459,145 US5693626A (en) 1993-12-21 1995-06-02 Tetrahydrofuran antifungals
US08/458,543 US5714490A (en) 1993-12-21 1995-06-02 Tetrahydrofuran antifungals
PCT/US1996/007547 WO1996038443A1 (en) 1995-06-02 1996-05-30 Tetrahydrofuran antifungals

Publications (1)

Publication Number Publication Date
MX9701229A true MX9701229A (es) 1997-05-31

Family

ID=27412736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701229A MX9701229A (es) 1995-06-02 1996-05-30 Antifungicos de tetrahidrofurano.

Country Status (19)

Country Link
EP (1) EP0773941B1 (es)
CN (1) CN1073109C (es)
AR (1) AR002751A1 (es)
AT (1) ATE240319T1 (es)
AU (1) AU5928096A (es)
CA (1) CA2197672C (es)
CZ (1) CZ59497A3 (es)
DE (1) DE69628117T2 (es)
ES (1) ES2199291T3 (es)
HK (1) HK1008821A1 (es)
HU (1) HUP9701690A3 (es)
IL (1) IL118464A (es)
MX (1) MX9701229A (es)
NO (1) NO971218D0 (es)
NZ (1) NZ309281A (es)
PL (1) PL319635A1 (es)
SK (1) SK27097A3 (es)
TW (1) TW357146B (es)
WO (1) WO1996038443A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9809744A (pt) 1997-02-11 2000-06-20 Janssen Pharmaceutica Nv Antifúngicos de azol contendo éster de aminoácido
WO1999018111A1 (en) * 1997-10-07 1999-04-15 Schering Corporation Crystalline antifungal glycine ester polymorph
AU759982B2 (en) * 1997-10-07 2003-05-01 Merck Sharp & Dohme Corp. Crystalline antifungal polymorph
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
WO2000030655A1 (en) 1998-11-20 2000-06-02 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
MXPA01011117A (es) 1999-05-04 2002-06-04 Janssen Pharmaceutica Nv Eteres antifungicos.
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
EP2451805A1 (en) 2009-07-09 2012-05-16 Sandoz AG A crystalline form of posaconazole
CN102234267A (zh) * 2010-04-21 2011-11-09 中国科学院上海药物研究所 新型三氮唑类抗真菌化合物、其药物组合物及其制备方法和用途
CN102906087B (zh) 2010-05-19 2016-03-23 桑多斯股份公司 制备手性三唑酮的方法
WO2011144657A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Purification of posaconazole and posaconazole intermediates
RU2580318C2 (ru) 2010-05-19 2016-04-10 Сандоз Аг Получение промежуточных продуктов для синтеза позаконазола
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
CN103635465A (zh) 2011-06-16 2014-03-12 桑多斯股份公司 制备手性化合物的方法
EP3024828B1 (en) 2013-07-25 2017-05-17 Sandoz AG Improved process for the preparation of crystalline form iv of posaconazole
ITMI20132114A1 (it) 2013-12-18 2015-06-19 Djada Pharmaceutical Sa Una forma cristallina di posaconazolo
CN104370894A (zh) * 2014-10-21 2015-02-25 江苏恒盛药业有限公司 无定型泊沙康唑的制备工艺
CN105622591B (zh) * 2014-11-06 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种新型三唑类抗真菌药物的制备方法
KR102579848B1 (ko) 2014-12-05 2023-09-18 풀모사이드 리미티드 항진균 화합물
CA2981945C (en) 2015-05-21 2023-08-29 Pulmocide Limited Antifungal 4-(4-(4-(((3r,5r)-5-((1 h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl) benzamide, or a pharmaceutically acceptable salt thereof
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
CN105606736A (zh) * 2016-01-27 2016-05-25 重庆华邦制药有限公司 分离测定泊沙康唑中间体z1及其有关物质的方法
CN107033186B (zh) * 2016-02-04 2020-06-09 武汉朗来科技发展有限公司 泊沙康唑衍生物、其药物组合物和用途
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
CN106866459A (zh) * 2017-03-30 2017-06-20 成都绿林科技有限公司 一种抗真菌药物中间体的制备方法
CN106986787A (zh) * 2017-03-30 2017-07-28 成都绿林科技有限公司 一种泊沙康唑中间体的合成方法
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途
CN113666915B (zh) * 2021-08-27 2022-08-16 江苏海洋大学 一种泊沙康唑中间体的制备方法
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals
CO4520281A1 (es) * 1993-12-21 1997-10-15 Schering Corp Antifungicos de tetrahidrofurano
HU227281B1 (en) * 1994-01-24 2011-01-28 Janssen Pharmaceutica Nv Watersoluble azole antifungals, process for their preparation intermediates, and pharmaceutical compositions containing the compounds

Also Published As

Publication number Publication date
IL118464A0 (en) 1996-09-12
EP0773941B1 (en) 2003-05-14
HK1008821A1 (en) 1999-05-21
ES2199291T3 (es) 2004-02-16
IL118464A (en) 2000-08-13
DE69628117T2 (de) 2004-04-01
HUP9701690A3 (en) 1998-04-28
CN1161038A (zh) 1997-10-01
HUP9701690A2 (hu) 1998-03-02
WO1996038443A1 (en) 1996-12-05
TW357146B (en) 1999-05-01
AU5928096A (en) 1996-12-18
DE69628117D1 (de) 2003-06-18
CZ59497A3 (en) 1997-08-13
CA2197672A1 (en) 1996-12-05
ATE240319T1 (de) 2003-05-15
NO971218L (no) 1997-03-17
NO971218D0 (no) 1997-03-17
CN1073109C (zh) 2001-10-17
PL319635A1 (en) 1997-08-18
CA2197672C (en) 2011-05-17
EP0773941A1 (en) 1997-05-21
SK27097A3 (en) 1997-09-10
NZ309281A (en) 1998-07-28
AR002751A1 (es) 1998-04-29

Similar Documents

Publication Publication Date Title
MX9701229A (es) Antifungicos de tetrahidrofurano.
KR0179990B1 (en) Tetrahydrofuran antifungals
CA2150287A1 (en) Agent for treating hepato-biliary diseases
CA2182244A1 (en) Camptothecin derivatives
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
AU6114699A (en) Naphthrydine compounds and their azaisosteric analogues as antibacterials
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
AU6257396A (en) Tetrahydrofuran antifungals
WO1999011651A3 (en) 3-descladinose 6-o-substituded erythromycin derivatives
CA2309485A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
AP2002002494A0 (en) Hygromycin derivatives.
CA2208032A1 (en) Substituted amidinonaphthyl ester derivative
MY133222A (en) Method of treating glaucoma and ischemic retinopathy